ACCORD HEALTHCARE LIMITED
Location
Founded
2004-04-13
Risk Signals
337 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products, Pharmaceutical Preparations, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about ACCORD HEALTHCARE LIMITED
Live alerts from global media, monitored by Business Radar
2020-12-22 (informa.com)
Accord Seeks To Capitalize On Portfolio And Partnerships
Accord expects to maintain its historically high growth rates through a“ holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’ s
Read more
2020-12-07 (informa.com)
Accord Expands CNS Ambitions With Zubsolv Deal
Accord Healthcare has struck a European licensing deal with Orexo for its Zubsolv opioid-dependence treatment, building on a CNS business that also includes a recent distribution agreement with Molteni Farmaceutici for Sixmo.
Read more
2020-10-23 (informa.com)
Henlius Finds Global Partner For Ophthalmic Bevacizumab
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.
Read more
2020-10-05 (informa.com)
Accord And Henlius Broaden Trastuzumab Alliance
Shanghai Henlius Biotech and Accord Healthcare have broadened their collaboration on trastuzumab, with the Chinese company licensing its Zercepac biosimilar to Accord in the US and Canada.
Read more